Finch Therapeutics Group Inc
Change company Symbol lookup
Select an option...
FNCH Finch Therapeutics Group Inc
TOL Toll Brothers Inc
TGEN Tecogen Inc
EPAM Epam Systems Inc
ISLE Isleworth Healthcare Acquisition Corp
THC Tenet Healthcare Corp
BKCC BlackRock Capital Investment Corp
VIR Vir Biotechnology Inc
CBH Virtus Convertible & Income 2024 Target Term Fund

Health Care : Biotechnology | Small Cap Growth
Company profile

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. It is engaged in leveraging its Human-First Discovery platform to develop a class of orally administered biological drugs. Its Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection (CDI). CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. Its product pipeline includes FIN-211, TAK-524, and FIN-525, as well as consortia product candidates.

Day's Change
-0.08 (-2.78%)
B/A Size
Day's High
Day's Low

Today's volume of 10,851 shares is on pace to be much lighter than FNCH's 10-day average volume of 197,256 shares.

Latest Earnings Consensus (Q1 ending 03/2022)Next Earnings Announcement
Announced May 16, 2022
--Q1 Consensus
of analysts
--Difference from
Q2 Earnings
will announce
(Unconfirmed) August 10, 2022

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.



FNCH's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.